Abstract
As part of the study “The burden of rheumatoid arthritis and patient access to treatment”, this paper reviews evidence on the health burden of rheumatoid arthritis (RA) in terms of morbidity (DALYs), mortality (% of deaths attributable to RA) and quality of life (utility and loss of QALYs), as well as the economic impact on society. Based on available literature on the prevalence and the cost of RA, combined with economic indicators, the annual cost per patient as well as the total national cost is estimated for Europe and North America (Canada and the United States), as well as Australia, Turkey, the Russian Federation and South Africa. Total costs to society were estimated at €45.3 billion in Europe and at €41.6 billion in the United States. Utility scores were found to be amongst the lowest compared to other diseases.
Similar content being viewed by others
References
Silman, A.: Epidemiology of rheumatic diseases. Oxford University Press, Oxford (1993)
Centers for Disease Control and Prevention: Prevalence of arthritis—US 1997. MMWR 50, 334–336, [CD] (2001)
Guillemin, F., Saraux, A., Guggenbuhl, P., et al.: Prevalence of rheumatoid arthritis in France: 2001. Ann. Rheum. Dis. 64, 1427–1430 (2005)
Alamanos, Y., Voulgari, P.V., Drosos, A.A.: Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology Criteria: a systematic review. Semin. Arthritis Rheum. 36, 182–188 (2006)
Andrianakos, A., Trontzas, P., Christoyannis, F., et al.: Prevalence of rheumatic diseases in Greece: a cross-sectional population-based epidemiological study. The ESORDIG Study. J. Rheumatol. 30, 1589–1601 (2003)
Carmona, L., Villaverde, V., Hernandez-Garcia, C., et al.: The prevalence of rheumatoid arthritis in the general population of Spain. Rheumatology (Oxford) 41(1), 88–95 (2002)
Cimmino, M.A., Parisi, M., Moggiana, G., et al.: Prevalence of rheumatoid arthritis in Italy: the Chiavari Study. Ann. Rheum. Dis. 57, 315–318 (1998)
Drosos, A.A., Alamanos, I., Voulgari, P.V., et al.: Epidemiology of adult rheumatoid arthritis in northwest Greece 1987–1995. J. Rheumatol. 24, 2129–2133 (1997)
Saraux, A., Guedes, C., Allain, J., et al.: Prevalence of rheumatoid arthritis and spondyloarthropathy in Brittany, France. Societe de Rhumatologie de l’Ouest J. Rheumatol. 26, 2622–2627 (1999)
Gabriel, S.E., Crowson, C.S., O’Fallon, W.M.: The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955–1985. Arthritis Rheum. 42, 415–420 (1999)
Hakala, M., Pollanen, R., Nieminen, P.: The ARA 1987 revised criteria select patients with clinical rheumatoid arthritis from a population based cohort of subjects with chronic rheumatic diseases registered for drug reimbursement. J. Rheumatol. 20, 1674–1678 (1993)
Power, D., Codd, M., Ivers, L., et al.: Prevalence of rheumatoid arthritis in Dublin, Ireland: a population based survey. Ir. J. Med. Sci. 168, 197–200 (1999)
Riise, T., Jacobsen, B.K., Gran, J.T.: Incidence and prevalence of rheumatoid arthritis in the county of Tromsö, northern Norway. J. Rheumatol. 27, 1386–1389 (2000)
Simonsson, M., Bergman, S., Jacobsson, L.T., et al.: The prevalence of rheumatoid arthritis in Sweden. Scand. J. Rheumatol. 28, 340–343 (1999)
Symmons, D., Turner, G., Webb, R., et al.: The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology (Oxford) 41, 793–800 (2002)
Uhlig, T., Kvien, T.K., Glennas, A., et al.: The incidence and severity of rheumatoid arthritis, results from a county register in Oslo, Norway. J, Rheumatol, 25, 1078–1084 (1998)
Rasch, E., Hirsch, R., Paulose-Ram, R., Hochberg, M.: Prevalence of rheumatoid arthritis in persons 60 years of age and older in the United States: effect of different methods of case classification. Arthritis Rheum. 48, 917–926 (2003)
Drosos, A., et al.: Rheumatoid Arthritis in Greek and British patients: a comparative clinical, radiologic, and serologic study. Arthritis Rheum. 35, 745–748 (1992)
Antoni, C., Maini, R., Grunke, M., et al.: Cooperative of QoL in Rheumatic disease: results of a survey among 6,000 patients across 11 European countries. Arthritis Rheum 46:ACR (abstract) (2002)
WHO Death and DALY estimates for 2002 by cause for WHO Member States, http://www.who.int/healthinfo/statistics/bodgbddeathdalyestimates.xls
Rupp, I., Boshuizen, H.C., Dinant, H.J., et al.: Disability and health-related quality of life among patients with rheumatoid arthritis: association with radiographic joint damage, disease activity, pain, and depressive symptoms. Scand. J. Rheumatol. 35, 175–181 (2006)
Young, A., Wilkinson, P., Talamo, J., et al.: Socioeconomic deprivation and rheumatoid disease. What lessons for the health service? Ann. Rheum. Dis. 59, 794–799 (2000)
Kobelt, G., Lindgren, P., Lindroth, Y., Jacobson, L., Eberhardt, K.: Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis. Rheumatology (Oxford) 44, 1169–1175 (2005)
Kobelt, G., Richard, B., Peeters, P., Sany, J.: Costs and quality of life of patients with RA in France. ACR 2006, Bone Joint Spine 75(7), (2008)
Currie, C.J., McEwan, P., Peters, J.R., Patel, T.C., Dixon, S.: The routine collation of health outcomes data from hospital-treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects. Value Health 8, 581–590 (2005)
Orme, M., Kerrigan, J., Tyas, D., Russell, N., Nixon, R.: The effect of disease, functional status and relapses ont he utility of people with multiple sclerosis in the UK. Value Health 10, 54–60 (2007)
Bloom, B.S., Bruno, D.J., Maman, D.Y., Jayadevappa, R.: Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 19, 207–213 (2001)
Koopmanschap, M.A.: Cost-of-illness studies. Useful for health policy? Pharmacoeconomics 14, 143–148 (1998)
Cooper, N.J.: Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford) 39, 28–33 (2000)
Pugner, K.M., Scott, D.I., Holmes, J.W., Hieke, K.: The costs of rheumatoid arthritis: an international long-term view. Semin. Arthritis Rheum. 29, 305–220 (2000)
Rosery, H., Bergemann, R., Maxion-Bergemann, S.: International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 23, 243–257 (2005)
Huscher, D., Merkesdal, S., Thiele, K., et al.: Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. Ann. Rheum. Dis. 65, 1175–1183 (2006)
Kirwan, J.R.: Conceptual issues in scoring radiographic progression in rheumatoid arthritis. J. Rheumatol. 26, 720–725 (1999)
Landewe, R.B., Boers, M., Verhoeven, A.C., et al.: COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis Rheum. 46, 347–356 (2002)
Kobelt, G., Jonsson, L., Lindgren, P., et al.: Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis. Arthritis Rheum. 46, 2310–2319 (2002)
Verstappen, S.M., Verkleij, H., Bijlsma, J.W., et al.: Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann. Rheum. Dis. 63, 817–824 (2004)
Hallert, E., Husberg, M., Skogh, T.: Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). Rheumatology (Oxford) 45, 325–331 (2006)
Michaud, K., Messer, J., Choi, H.K., Wolfe, F.: Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 48, 2750–2762 (2003)
Kobelt, G., Eberhardt, K., Jonsson, L., Jonsson, B.: Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum. 42, 347–356 (1999)
Hulsemann, J.L., Ruof, J., Zeidler, H., Mittendorf, T.: Costs in rheumatology: results and lessons learned from the ‘Hannover Costing Study’. Rheumatol. Int. 26, 704–711 (2006)
Lajas, C., Abasolo, L., Bellajdel, B., et al.: Costs and predictors of costs in rheumatoid arthritis: a prevalence-based study. Arthritis Rheum. 49, 64–70 (2003)
Albers, J.M., Kuper, H.H., van Riel, P.L., et al.: Socio-economic consequences of rheumatoid arthritis in the first years of the disease. Rheumatology (Oxford) 38, 423–430 (1999)
Merkesdal, S., Ruof, J., Schoffski, O., et al.: Indirect medical costs in early rheumatoid arthritis: composition of and changes in indirect costs within the first three years of disease. Arthritis Rheum. 44, 528–534 (2001)
Young, A., Dixey, J., Cox, N., et al.: How does functional disability in early rheumatoid arthritis (RA) affect patients and their lives? Results of 5 years of follow-up in 732 patients from the Early RA Study (ERAS). Rheumatology (Oxford) 39, 603–611 (2000)
Fex, E., Larsson, B-M., Nived, K., Eberhardt, K.: Impact of rheumatoid arthritis on work status and social and leisure time activities in patients followed 8 years from onset. J. Rheumatol. 25, 44–50 (1997)
Merkesdal, S., Huelsemann, J.L., Mittendorf, T., et al.: Productivity costs of rhumatoid arthritis in Germany: cost composition and prediction of main cost components (in German). Z. Rheumatol. 65, 527–534 (2006)
Chorus, A.M., Miedema, H.S., Wevers, C.J., van Der Linden, S.: Labour force participation among patients with rheumatoid arthritis. Ann. Rheum. Dis. 59, 549–554 (2000)
Young, A., Dixey, J., Kulinskaya, E., et al.: Which patients with early RA stop working? Results from a 5-year inception cohort of 547 patients. Ann. Rheum. Dis. 61, 335–340 (2002)
Meenan, R.F., Yelin, E.H., Henke, C.J., et al.: The costs of rheumatoid arthritis. A patient-oriented study of chronic disease costs. Arthritis Rheum. 21, 827–833 (1978)
Liang, M.H., Larson, M., Thompson, M., et al.: Costs and outcomes in rheumatoid arthritis and osteoarthritis. Arthritis Rheum. 27, 522–529 (1984)
Lubeck, D.P., Spitz, P.W., Fries, J.F., et al.: A multicenter study of annual health service utilization and costs in rheumatoid arthritis. Arthritis Rheum. 29, 488–493 (1986)
Wolfe, F., Kleinheksel, S.M., Spitz, P.W., et al.: A multicenter study of hospitalization in rheumatoid arthritis. Frequency, medical-surgical admissions, and charges. Arthritis Rheum. 29, 614–619 (1986)
Bloom, B.S.: Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis. Am. J. Med. 84, 20–24 (1988)
Gabriel, S.E., Crowson, C.S., Campion, M.E., O’Fallon, W.M.: Direct medical costs unique to people with arthritis. J. Rheumatol. 24, 719–725 (1997)
Gabriel, S.E., Crowson, C.S., Campion, M.E., O’Fallon, W.M.: Indirect and nonmedical costs among people with rheumatoid arthritis and osteoarthritis compared with nonarthritic controls. J. Rheumatol. 24, 43–48 (1997)
Lanes, S.F., Lanza, L.L., Radensky, P.W., et al.: Resource utilization and cost of care for rheumatoid arthritis and osteoarthritis in a managed care setting: the importance of drug and surgery costs. Arthritis Rheum. 40, 1475–1481 (1997)
Ward, M.M., Javitz, H.S., Yelin, E.H.: The direct cost of rheumatoid arthritis. Value Health 3, 243–252 (2000)
Yelin, E.: The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J. Rheumatol. 44 (Suppl), 47–51 (1996)
Yelin, E., Wanke, L.A.: An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum. 42, 1209–1218 (1999)
Andlin-Sobocki, P., Jonsson, B., Wittchen, H.U., Olesen, J.: Cost of disorders of the brain in Europe. Eur. J. Neurol. 12(Suppl 1), 1–27 (2005)
OECD health data (2006) OECD Geneva
Eurostat (2006) Economy and finance, Brussels
The Word Bank (2007) http://www.worldbank.org
Kobelt, G., Berg, J., Lindgren, P., Fredrikson, S., Jönsson, B.: Costs and quality of life of multiple sclerosis in Europe. J. Neurol. Neurosurg. Psychiatry 77, 918–926 (2006)
Wagner, E., Lackerbauer, E., Siegmeth, W.: Direct and indirect costs of rheumatoid arthritis and the socio-emotional effects of this disease—an Austrian study (in German). Wien Med Wochenschr 155, 217–226 (2005)
Westhovens, R., Boonen, A., Verbruggen, L., et al.: Healthcare consumption and direct costs of rheumatoid arthritis in Belgium. Clin. Rheumatol. 24, 615–619 (2005)
Maetzel, A., Li, L.C., Pencharz, J., et al.: The economic burden associated with osteoarthritis, rheumatoid arthritis, and hypertension: a comparative study. Ann. Rheum. Dis. 63, 395–401 (2004)
Sorensen, J.: Health care costs attributable to the treatment of rheumatoid arthritis. Scand. J. Rheumatol. 33, 399–404 (2004)
Leardini, G., Salaffi, F., Montanelli, R., et al.: A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin. Exp. Rheumatol. 20, 505–515 (2002)
Verstappen, S.M., Jacobs, J.W., van der Heijde, D.M., et al.: Utility and direct costs: ankylosing spondylitis compared with rheumatoid arthritis. Ann. Rheum. Dis. (2006)
Jacobsson, L.T., Lindroth, Y., Marsal, L., Juran, E., Bergstrom, U., Kobelt, G.: Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmo, Sweden. Scand. J. Rheumatol. 36, 179–183 (2007)
Kobelt, G., Lindgren, P., Singh, A., Klareskog, L.: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis. 64, 1174–1179 (2005)
McIntosh, E.: The cost of rheumatoid arthritis. Br. J. Rheumatol. 35, 781–790 (1996)
Sobocki, P., Pugliatti, M., Lauer, L., Kobelt, G.: Estimation of the cost of MS in Europe: extrapolations from a multinational cost study. Mult. Scler. 13, 1054–1064 (2007)
Conflict of interest
This study has been funded by unrestricted grant from F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Author information
Authors and Affiliations
Corresponding author
Additional information
It should be noted that the studies on which the estimates are based were conducted at different points in time. As noted earlier, drugs costs have likely increased over time, in particular after the introduction of the new biological agents. Also, informal care costs are based on limited data.
Rights and permissions
About this article
Cite this article
Lundkvist, J., Kastäng, F. & Kobelt, G. The burden of rheumatoid arthritis and access to treatment: health burden and costs. Eur J Health Econ 8 (Suppl 2), 49–60 (2008). https://doi.org/10.1007/s10198-007-0088-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10198-007-0088-8